HOME >> MEDICINE >> NEWS
CRESTOR leads in 1st international prospective study of statins in the metabolic syndrome

London, United Kingdom, Monday 6 September 2004. New data from the first international prospective study of statin treatment in people with the metabolic syndrome demonstrate that CRESTORTM (rosuvastatin) achieves excellent results in lowering LDL-cholesterol (LDL-C) and raising HDL-C in this important and growing patient population.1 Today's results from the COMETS study, presented at the 40th Annual Meeting of the European Association for the Study of Diabetes (EASD), Munich, Germany, show that CRESTOR 10mg lowers LDL-C and raises HDL-C significantly more than atorvastatin 10mg in patients with the metabolic syndrome and raised LDL-C.1

People with the metabolic syndrome, which affects nearly one in five men and nearly one in four women, are nearly twice as likely to die from cardiovascular disease and their risk of heart attack and stroke is threefold.2 ,3 The term 'metabolic syndrome' describes a clustering of three or more cardiovascular risk factors, including abdominal obesity, elevated triglycerides, low HDL-C (or 'good' cholesterol), hypertension and elevated blood glucose.4 For these 'high risk' patients, lowering LDL-C levels is the primary lipid treatment target to reduce their cardiovascular risk, as highlighted in both the US National Cholesterol Education Programme's Adult Treatment Panel III (US NCEP ATP III) guidelines and the recently revised European Guidelines on Cardiovascular Disease Prevention in Clinical Practice.4-6 Sub-group analyses of long-term studies have also shown that statin treatment in people with the metabolic syndrome can reduce cardiovascular events.7,8

The COMETS study, part of the GALAXY ProgrammeTM, assessed both the effect of CRESTOR 10mg compared to atorvastatin 10mg and placebo at six weeks and, following titration, CRESTOR 20mg and atorvastatin 20mg at 12 weeks. The results in 397 patients with the metabolic syndrome (
'"/>

Contact: Rachael Wood
rachael.wood@astrazeneca.com
44-162-551-9514
Shire Health International
6-Sep-2004


Page: 1 2 3 4

Related medicine news :

1. 1st data show CRESTOR highly effective at lowering LDL-C in patients with type 2 diabetes
2. CRESTOR (TM) improves apolipoprotein and lipid ratios - markers of cardiovascular disease risk
3. Corrected metabolism leads to health benefits and weight loss
4. Combining PET and CT scans leads to more accurate radiation therapy for lung cancer patients
5. Lack of specific collagen type leads to osteoarthritis
6. UCI study uncovers how plaque in neck artery leads to stroke-inducing blood clots
7. Vaginal hysterectomy leads to better outcomes than abdominal surgery
8. Little evidence that breast cancer diagnosis leads to employment discrimination, study concludes
9. Marine sponge leads researchers to immune system regulator
10. Safer drug prescribing for seniors in nursing homes: Canada leads the way
11. Malnutrition in early years leads to low IQ and later antisocial behavior, USC study finds

Post Your Comments:
(Date:7/2/2015)... ... ... Following the recent report by JAMA Internal Medicine published on June ... Becic emphatically declared a war on obesity in the United States. , "Obesity is ... understand the magnitude of this discovery. For that reason, I am declaring, along with ...
(Date:7/2/2015)... (PRWEB) , ... July 02, 2015 , ... ... the parking structure retrofit project at the University of Minnesota, they knew it ... that it would also be an award-winning choice: the total energy savings after ...
(Date:7/2/2015)... , ... July 02, 2015 , ... With summer in full swing, Americans are flocking ... one of the top spots for fishing in the world, and it’s easy to understand ... Ontario, Canada has great fish. , Recreational fishing is a huge industry, and Americans ...
(Date:7/2/2015)... ... 2015 , ... “ LIFX ” was featured on NewsWatch as part of ... consumers. Amanda Forstrom, a technology expert and special reporter for NewsWatch, conducted the review ... bulbs on the market. , According to the U.S. Department of Energy, it’s very ...
(Date:7/2/2015)... ... July 02, 2015 , ... ... of the SIGVARIS PERFORMANCE SOCKS. Since the socks were first introduced, they have ... Their significant popularity has inspired four new, fun shades including: blue, lime, pink ...
Breaking Medicine News(10 mins):Health News:Samir Becic's Health Fitness Revolution Declares War Against Obesity in America 2Health News:Samir Becic's Health Fitness Revolution Declares War Against Obesity in America 3Health News:Samir Becic's Health Fitness Revolution Declares War Against Obesity in America 4Health News:Kenall’s TekDek™ Helps University Achieve Award-Winning Energy Savings in Parking Structure Lighting Retrofit 2Health News:The Most Versatile Smart Light Bulbs were featured on NewsWatch Television 2Health News:SIGVARIS is Sporting Four Brand New Colors in the Popular PERFORMANCE SOCK Product Line 2
(Date:7/3/2015)... YORK , July 3, 2015  Obsidian HDS, ... - an online service for the management of data ... announced today that PharmaShine now includes the 2014 Open ... for Medicare Services on June 30. The data disclosed ... million transactions between industry and providers totaling $6.49 billion ...
(Date:7/2/2015)... BGI a annoncé aujourd,hui que son ... situé à Hong Kong ... Pathologists  (Collège des pathologistes américains, ou CAP). Les ... constituent le premier laboratoire clinique de ... du CAP en Chine, car il satisfait les ...
(Date:7/2/2015)... ResMed Inc. (NYSE: RMD ) today announced that it ... 30, 2015 results on Thursday, July 30, 2015, after the ... ResMed,s results will be issued after 1:00 p.m. US Pacific ... operating results and future outlook. The earnings call ... and the live webcast of the call can be accessed ...
Breaking Medicine Technology:New Open Payments (Sunshine Act) Data Now Searchable on PharmaShine 2BGI obtient la certification du Collège des pathologistes américains (CAP) 2ResMed to Announce Fourth Quarter and Fiscal Year-End 2015 Results 2
Cached News: